News
Keep Up with GlycoMira
Press Releases
GlycoMira receives $2.8M from the National Institute of Dental and Craniofacial Research (NIH) for oral mucositis drug development.
October 29, 2021
GlycoMira receives $2M from the National Institute of Allergy and Infectious Diseases (NIH) for chronic rhinosinusitis drug development
June 24, 2021
Other News
© GlycoMira Therapeutics, Inc.
All rights reserved.